Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
very Fat dildos!
Popular Articles

Nutrient-Rich Foods Index Aims To Reshape Nutrition Education
WHAT: The Nutrient-Rich Foods (NRF) Index is a new, objective, science-based way to measure the total nutritional quality of foods and beverages.
diet pills Prezzi dentisti croazia
Family Of Murdered Abortion Provider Tiller Announces Permanent Closure Of Clinic
The family of murdered Kansas abortion provider George Tiller announced on Tuesday that his Wichita clinic will not re-open, leading some abortion-rights advocates to voice concern about access to the procedure, the New York Times reports. Tiller was one of a handful of abortion providers who performed the procedure in the second and third trimesters of pregnancy, and women for decades have traveled to the clinic from across the U.S. and other countries. The clinic, Women"s Health Care Services, also was Kansas" only clinic outside the Kansas City area (Davey, New York Times, 6/10). The Tiller family said in a statement that the clinic will be "permanently closed" effective immediately. The family also said it does not plan to be involved "in any similar clinic" but will "honor Dr. Tiller"s memory through private charitable activities" (Slevin/Stein, Washington Post, 6/10).While abortion-rights advocates expressed empathy for the family, some added that they also are concerned that the clinic"s closure could have devastating effects for women who learn of fatal health problems late in their pregnancies, the Times reports. Nancy Northup, president of the Center for Reproductive Rights, said, "It is unacceptable that antiabortion intimidation and violence has led to the closing of Dr. Tiller"s clinic." She added, "Not only have we lost a fearless defender of women"s fundamental health and rights in Dr. Tiller"s murder, but the closing of his clinic leaves an immediate and immense void in the availability of abortion" (New York Times, 6/10). Suzanne Poppema, board chair of Physicians for Reproductive Choice and Health and a retired ob-gyn who performed abortions, said that abortions later in pregnancy would still be available, including through university hospitals that do not advertise the service. The closing is "not going to stop people who want to provide the service, but it will slow them down," she said. Marla Patrick, Kansas coordinator for the National Organization for Women, said abortion-rights advocates are working to open another Wichita-based clinic that provides abortions later in pregnancy (Bello, USA Today, 6/10). The AP/Yahoo! News reports that Kansas state law permits abortion after 21 weeks" gestation only if continuing the pregnancy would endanger the woman"s life or cause a "substantial and irreversible impairment" of a major bodily function, which courts have interpreted to include the mental health of the woman (Hegman/Hanna, AP/Yahoo! News, 6/9).According to the Times, some abortion-rights advocates had hoped other abortion providers would take over Tiller"s work at the clinic. LeRoy Carhart, a Nebraska abortion provider who also worked with Tiller, said he is "currently exploring every option to be able to continue to make second- and early, medically indicated third-trimester abortions available." Warren Hern, a Colorado abortion provider who performs procedures later in pregnancy, said, "Where does it end? The antiabortion fanatics got exactly what they wanted" (New York Times, 6/10). According to the Wall Street Journal, abortion-rights opponents" response to the closure was "subdued." Some expressed concern that antiabortion-rights extremists would think that violence "gets results where legal protest doesn"t," the Journal reports (Simon, Wall Street Journal, 6/10). Troy Newman, president of Operation Rescue, said that while the group is "thankful" that the clinic is closed, they "wish it would have come through the peaceful, legal channels that we were pushing" (New York Times, 6/10).Broadcast CoverageMSNBC"s "The Rachel Maddow Show" on Tuesday reported on the clinic"s closure and included a discussion with Susan Hill, president of the National Women"s Health Organization, about violence against abortion providers and an increase in the hostility of protesters outside abortion clinics since Tiller"s murder (Maddow, "The Rachel Maddow Show," MSNBC, 6/9). NPR"s "All Things Considered" on Tuesday also reported on the clinic"s closure ("All Things
News of the day
Change In Measurement Of HBA1C For People With Diabetes, UK
From 1 June 2009, HbA1c (long term blood glucose levels) in all people with diabetes will be measured in millimoles per mol as well as by percentage, the Department of Health said today.
Oncology

SPECT MPI With Cardiolite(R) Used In BARI 2D Study To Evaluate Type 2 Diabetes And Coronary Artery Disease Treatment Strategies

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announced today that the company"s leading imaging agent, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease. The results of this study, known as The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), will be presented by the University of Pittsburgh Graduate School of Public Health at a special symposium on Sunday, June 7, 2009, from 4:15 p.m. - 5:15 p.m. (CT) at the American Diabetes Association 69th Scientific Sessions in New Orleans. In the study, SPECT myocardial perfusion imaging (MPI) with Cardiolite® was used to objectively identify coronary artery disease during initial patient recruitment and for subsequent one, three and five-year follow-up of patients enrolled in the study to determine the impact of therapy on left ventricular ejection fraction (LVEF), ischemic burden and scar. One of the two primary objectives for the BARI 2D study was to determine if a strategy of initial elective coronary revascularization combined with aggressive medical therapy results in a lower five-year mortality compared with a strategy of initial aggressive medical therapy alone. Lantheus Medical Imaging, Inc. provided support for the study. "As the number of patients affected by a combination of type 2 diabetes and coronary artery disease continues to rapidly increase, the results of the BARI 2D study could potentially impact millions and better inform patient management decisions as clinicians seek to establish the best possible course of treatment for this growing patient population," stated Don Kiepert, president and chief executive officer of Lantheus Medical Imaging, Inc. "We are proud to have supported and supplied our product for this pivotal clinical effort and recognize the importance of improving treatment protocols for patients with type 2 diabetes to manage cardiovascular risk and prevent further complications." About Cardiolite® Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) is one of the world"s most widely-used cardiac imaging agents and the only technetium labeled myocardial perfusion agent that has been used to image more than 40 million patients. For almost two decades, Cardiolite® has played a vital role in the diagnosis and management of patients with known or suspected coronary artery disease. Cardiolite® is the first technetium labeled myocardial perfusion tracer to provide physicians with prognostic information that can be helpful in making patient management decisions. Cardiolite® is the subject of more than 10,000 publications and the imaging agent of choice within several post marketing cardiology clinical trials -DIAD, COURAGE, ERASE, INSPIRE and CHRISTMAS - which have resulted in changes in patient care. Cardiolite® leads the way with the most FDA approved clinical indications as a myocardial perfusion imaging agent. Indication and Important Safety Information Regarding Cardiolite® Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent"s labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Exercise and pharmacologic stress testing should be performed only under the supervision of a qualified physician. Cardiolite® has been rarely associated with acute severe allergic events of angioedema and urticaria. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell. For full prescribing information, please visit http://www.cardiolite.com. Cardiolite® is a registered trademark of Lantheus Medical Imaging, Inc. Lantheus Medical Imaging, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009